LifeStance Health Group, Inc. (LFST)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of LifeStance Health Group, Inc. ("LifeStance” or the "Company") (NASDAQ: LFST). The investigation concerns whether LifeStance and certain of its officers and/or directors have violated federal securities laws.
On or around June 10, 2021, LifeStance conducted its initial public offering (“IPO”), selling 32.8 million shares priced at $18.00 per share. Then, on August 11, 2021, LifeStance reported its financial and operating results for the second quarter of 2021. Among other items, LifeStance reported a net loss for the quarter more than double that incurred in the same period in the prior year and estimated third quarter revenues that fell short of consensus expectations. During an earnings call that same day, the Company’s senior management in part blamed increased clinician turnover for the downward pressure on financial performance, indicating that they had identified this trend at least as early as midway through the second quarter of 2021, and explained that new clinicians would be less productive for up to six months. On this news, LifeStance’s stock price fell $10.16 per share, or 46.46%, to close at $11.71 per share on August 12, 2021.
If you are aware of any facts relating to this investigation, or purchased LifeStance shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.